Sensus Healthcare, Inc. ((SRTS)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sensus Healthcare’s latest earnings call painted a cautiously optimistic picture, as management balanced sharp near‑term financial pressure with meaningful strategic progress. Executives highlighted new reimbursement wins, growing treatment volumes and recurring revenue initiatives, even as revenue fell sharply and margins compressed. The tone was sober about current challenges but confident about a gradual path back to profitability.
New CPT Codes Clarify Reimbursement Landscape
New dedicated CPT codes for superficial radiotherapy, effective in 2026, were a central theme, giving dermatologists clearer billing pathways. Management said these codes are already boosting confidence among practices, simplifying coding and supporting broader adoption of SRT as an alternative to surgery.
Reimbursement Increase Transforms Physician Economics
The company underscored an approximate 300% increase in the per‑fraction delivery code, which dramatically improves economics for physicians delivering SRT. This richer reimbursement framework is driving higher inquiry levels and a stronger sales pipeline, particularly among dermatology groups evaluating new revenue streams.
Stable Shipments Support Installed Base Expansion
Sensus shipped 14 SRT systems in the quarter, matching the prior quarter and bringing its global installed base to about 965 systems. Of these, 10 were direct sales and four were placed under Fair Deal or rental arrangements, and management expects shipments to grow sequentially as the year progresses.
Recurring Revenue and Utilization Show Momentum
Treatment volumes climbed 8% year over year, signaling rising utilization of the installed base. With 18 active FDA sites and nine more pending activation, the company emphasized that rentals, service and software are becoming increasingly important drivers of recurring, utilization‑based revenue.
SensusLink Launch Targets Software and Physics Revenue
The newly launched SensusLink platform is now live at several accounts and is designed to add a software and services layer to the SRT offering. Beyond workflow benefits, the tool enables billing for radiation physics consult codes, with management citing an example of about $93.85 per week in reimbursement over a typical ten‑week treatment protocol.
Shift Toward Purchases Improves Customer Breakeven
Roughly 70% of systems shipped in the quarter were outright purchases rather than FDA placements, reflecting a shift toward ownership. With an average breakeven of only about two patients per month, Sensus argued that practices can recoup their investment quickly, which may accelerate conversion from rentals to purchases.
Balance Sheet Strength Supports Transition
The company ended the quarter with $18.3 million in cash and no debt, a key cushion as it navigates a transition toward more recurring revenue. Management said this liquidity allows continued investment in commercial expansion and software initiatives without resorting to heavy balance sheet leverage.
Disciplined Cost Controls Reduce Operating Expenses
Operating expenses trended lower year over year, with G&A down to $2.0 million, selling and marketing at $1.7 million and R&D at $1.6 million. These reductions reflect concerted cost discipline and help offset some of the pressure from weaker revenue and margin performance.
Pipeline Strength and New Financing Options
Lead generation from major dermatology conferences, including key specialty meetings, remained robust, feeding a broader pipeline across independent practices, networks and hospital systems. To improve conversion, Sensus introduced its own financial services offering, providing more flexible financing options to prospective buyers.
Revenue Contracts Amid Loss of Key Customer
Quarterly revenue fell to $3.4 million from $8.3 million a year earlier, a decline of about 59%, largely because its historically largest customer made no purchases. Management noted that this customer is not included in current‑year models, so any renewed buying would represent upside rather than a baseline assumption.
Gross Margin Hit by Mix and Timing Effects
Gross profit dropped to $1.0 million and gross margin shrank to 29.2% from 52.2%, reflecting significant margin compression. The decline was driven by a higher share of international shipments with lower ASPs and more Fair Deal or rental placements, which are recognized over time instead of upfront.
Adjusted EBITDA Loss Widens Despite Flat Net Loss
Adjusted EBITDA loss widened to $4.2 million from $2.5 million, underscoring the impact of lower revenue and mix on underlying profitability. However, net loss remained roughly flat at $2.6 million, or $0.16 per share, suggesting that cost cuts and non‑cash items partially offset operating headwinds.
Revenue Recognition and Inventory Build Add Risk
Management highlighted that more rentals and Fair Deal arrangements delay revenue recognition, weighing on near‑term results even as installed base grows. Inventory rose to $16.5 million, up about 13%, which could pressure working capital if demand conversion or shipment timing falls short of expectations.
Customer Concentration Remains a Wildcard
The absence of purchases from the company’s largest historical customer underscores ongoing concentration risk. While management has deliberately excluded this customer from its outlook, investors were reminded that future orders from this account could materially affect revenue trends, either positively or negatively.
Guidance Signals Sequential Improvement and Profitability Goal
Looking ahead, management guided that second‑quarter revenue should exceed the first quarter’s $3.4 million, with the second half of the year topping the first half. They reiterated a goal of progressing toward full‑year profitability, supported by rising treatment volumes, expanded recurring revenue from rentals and software, and the tailwind of higher reimbursement.
Sensus Healthcare’s earnings call left investors with a nuanced view: fundamentals around reimbursement, utilization and recurring revenue appear to be improving, even as headline metrics like revenue and margin remain under pressure. If management executes on its shipment pipeline and software rollout while controlling costs, the company could emerge from this transition phase in a stronger competitive position.